Levetiracetam: The first SV2A ligand for the treatment of epilepsy

Expert Opinion on Drug Discovery

Volumn 2, Issue 11, 2007, Pages 1537-1545

  Klitgaard, Henrik ^a   Verdru, Peter ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Antiepileptic drug; Epilepsy; Keppra; Levetiracetam; Protein 2A; Synaptic vesicle

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CELL PROTEIN; ETIRACETAM; PLACEBO; SYNAPTIC VESICLE PROTEIN 2A; UNCLASSIFIED DRUG;

ADD ON THERAPY; AGGRESSION; AGITATION; ANGER; ANXIETY; APATHY; ARTICLE; ASTHENIA; ATAXIA; BEHAVIOR DISORDER; BINDING AFFINITY; BRAIN ELECTROPHYSIOLOGY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COORDINATION DISORDER; DEPERSONALIZATION; DEPRESSION; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG POTENCY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPILEPSY; FATIGUE; FOOD AND DRUG ADMINISTRATION; GAIT DISORDER; HOSTILITY; HUMAN; IRRITABILITY; MENTAL INSTABILITY; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; SOMNOLENCE; TEMPORAL LOBE EPILEPSY;

EID: 36649032950     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.11.1537     Document Type: Article

References (37)

1. LÖSCHER W, SCHMIDT D: Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. (1994) 172:95-134.
2. KUPFERBERG HJ: Antiepileptic drug development program: a cooperative effort of government and industry. Epilepsia (1989) 30(Suppl. 1):551-556.
3. KLITGAARD H, MATAGNE A, GOBERT J, WULFERT E: Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. (1998) 353(2-3):191-206.
4. LÖSCHER W, HÖNACK D: Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol. (1993) 232:147-158.
5. GOWER AJ, HIRSCH E, BOEHRER A, NOYER M, MARESCAUX C: Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. (1995) 223:207-213.
6. KLITGAARD H: Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia (2001) 42(Suppl. 4):13-18.
7. MARGINEANU DG, KLITGAARD H: Levetiracetam mechanisms of action. In: Antiepileptic Drugs (5th Edition). Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds), Lippincott, Williams & Wilkins, Baltimore, MD (2002):419-427.
8. KLITGAARD H, MATAGNE A, GRIMEE R, VANNESTE-GOEMAERE J, MARGINEANU DG: Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy. Seizure (2003) 122:92-100.
9. MARGINEANU DG, KLITGAARD H: Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol. Res. (2000) 424:281-285.
10. NIESPODZIANY I, KLITGAARD H, MARGINEANU DG: Desynchronizing effect of levetiracetam on epileptiform responses in rat hippocampal slices. Neuroreport (2003) 149:1273-1276.
11. RIGO JM, HANS G, NGUYEN L et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br. J. Pharmacol. (2002) 1365:659-672.
12. COULTER DA: Chronic epileptogenic cellular alterations in the limbic system after status epilepticus. Epilepsia (1999) 40(Suppl. 1):S23-S33.
13. 2+ current in pyramidal neurones of rat hippocampal slices. Neurosci. Lett. (2001) 306(1-2):5-8.
14. LUKYANETZ EA, SHKRYL VM, KOSTYUK PG: Selective blockade of N-type calcium channels by levetiracetam. Epilepsia (2002) 431:9-18.
15. MARGINEANU DG, WÜLFERT E: Inhibition by levetiracetam of a non-GABAA receptor-associated epileptiform effect of bicuculline in rat hippocampus. Br. J. Pharmacol. (1997) 1226:1146-1150.
16. WÜLFERT E, MARGINEANU DG: Thapsigargin inhibits bicuculline-induced epileptiform excitability in rat hippocampal slices. Neurosci. Lett. (1998) 243:141-143.
17. MARGINEANU DG, KLITGAARD H: Caffeine-induces epileptiform field potentials in rats hippocampal slices: a pharmacological characterization. Neuropharmacology (2004) 47:926-934.
18. 2+ transients and epileptiform potentials in hippocampal neurons. Neuroreport (2003) 143:471-475.
19. 2+] Increase induced by ATP and bradykinin in PC12 cells. J. Pharmacol. Exp. Ther. (2005) 3132:720-730.
20. NOYER M, GILLARD M, MATAGNE A, HENICHART JP, WÜLFERT E: The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. (1995) 2862:137-146.
21. FUKS B, GILLARD M, MICHEL P et al.: Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. Eur. J. Pharmacol. (2003) 4781:11-19.
22. LYNCH BA, LAMBENG N, NOCKA K et al.: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. USA (2004) 10126:9861-9866.
23. BAJJALIEH SM, PETERSEN K, SHINGHAL R, SCHELLER RH: SV2, a brain synaptic vesicle protein homologous to bacterial transporters. Science (1992) 257(5074):1271-1273.
24. BAJJALIEH SM, FRANTZ GD, WEIMANN JM, MCCONNELL SK, SCHELLER RH: Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J. Neurosci. (1994) 149:5223-5235.
25. CROWDER KM, GUNTHER JM, JONES TA et al.: Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc. Natl. Acad. Sci. USA (1999) 9626:15268-15273.
26. 1+ regulators in neurotransmitter release. Neuron (1999) 244:1003-1016.
27. GILLARD M, FUKS B, MICHEL P, VERTONGEN P, MASSINGHAM R, CHATELAIN P: Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain. Eur. J. Pharmacol. (2003) 478:1-9.
28. SHORVON SD, LOWENTHAL A, JANZ D, BIELEN E, LOISEAU P: Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European levetiracetam study group. Epilepsia (2000) 419:1179-1186.
29. CEREGHINO JJ, BITON V, ABOU-KHALIL B, DREIFUSS F, GAUER LJ, LEPPIK I: Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology (2000) 552:236-242.
30. BEN MENACHEM E, FALTER U: Efficacy and tolerability of levetiracetam 3000 mg/day in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European levetiracetam study group. Epilepsia (2000) 4110:1276-1283.
31. MORRELL MJ, LEPPIK I, FRENCH J et al.; THE KEEPER™ TRIAL: Levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res. (2003) 54:153-161 [Corrigendum: Epilepsy Res. (2003) 56:209-210].
32. FERRENDELLI JA, FRENCH J, LEPPIK I et al.: Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the Keeper trial. Epilepsy Behav. (2003) 4:702-709.
33. STEINHOFF BJ, SOMERVILLE ER, VAN PAESSCHEN W et al.; FOR THE N01031 (SKATE™) STUDY GROUP: The SKATE™ study: An open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Epilepsy Res. (2007) (In Press).
34. GLAUSER TA, AYALA R, ELTERMAN RD et al.: Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. N159 study group. Neurology (2006) 6611:1654-1660.
35. VERDRU P, WAJGT A, SCHIEMANN DELGADO J, NOACHTAR S: Efficacy and safety of levetiracetam 3000 mg/day as adjunctive treatment in adolescents and adults suffering from idiopathic generalised epilepsy with myoclonic seizures. Epilepsia (2005) 46(Suppl. 6):56-57.
36. BERKOVIC SF, KNOWLTON RC, LEROY RF et al.; ON BEHALF OF THE LEVETIRACETAM N01057 STUDY GROUP: Placebo-controlled study of levetiracetam in idiopathic generalised epilepsy. Neurology (2007) (In Press).
37. BRODIE MJ, PERUCCA E, RYVLIN P, BEN-MENACHEM E, MEENCKE HJ; LEVETIRACETAM MONOTHERAPY STUDY GROUP: Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology (2007) 686:402-408.